KEFLET
LOE ApproachingNDAORALTABLET
Approved
Oct 1972
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KEFLET is an oral tablet small molecule NDA approved by Eli Lilly in 1972. The specific indication and mechanism of action are not documented in available data. This legacy product represents a foundational asset in Lilly's portfolio with over 50 years of market presence.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team right-sizing and transition to generic defense or portfolio repositioning activities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
No current linked job openings are associated with KEFLET, reflecting its mature, LOE-approaching status. Career opportunities are limited and will likely focus on defensive commercial strategies, compliance, and managed transition activities rather than growth and innovation.
Brand ManagerField Sales Representative
Worked on KEFLET at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.